BCL-2 family regulation by the 20S proteasome inhibitor bortezomib.

Abstract

Bortezomib (Velcade, PS341) was licensed in 2003 as a first-in-class 20S proteasome inhibitor indicated for treatment of multiple myeloma, and is currently being evaluated clinically in a range of solid tumours. The mechanisms underlying its cancer cell toxicity are complex. A growing body of evidence suggests proteasome inhibition-dependent regulation of the BCL-2 family is a critical requirement. In particular, the stabilization of BH3-only proteins BIK, NOXA and BIM, appear to be essential for effecting BAX- and BAK-dependent cell death. These mechanisms are reviewed and the implications for favourable novel drug interactions are highlighted.

0100200300200920102011201220132014201520162017
Citations per Year

973 Citations

Semantic Scholar estimates that this publication has 973 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Fennell2008BCL2FR, title={BCL-2 family regulation by the 20S proteasome inhibitor bortezomib.}, author={D A Fennell and A Chacko and L Mutti}, journal={Oncogene}, year={2008}, volume={27 9}, pages={1189-97} }